Personalis, Inc. (NASDAQ:PSNL) Stake Boosted by XTX Topco Ltd

XTX Topco Ltd increased its stake in Personalis, Inc. (NASDAQ:PSNL) by 147.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,666 shares of the company’s stock after purchasing an additional 49,197 shares during the quarter. XTX Topco Ltd owned approximately 0.09% of Personalis worth $290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its stake in Personalis by 18.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock worth $62,000 after purchasing an additional 2,724 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Personalis in the 4th quarter worth about $28,000. Stifel Financial Corp increased its stake in Personalis by 25.0% in the 4th quarter. Stifel Financial Corp now owns 25,000 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after acquiring an additional 5,654 shares during the period. Finally, Two Sigma Advisers LP boosted its position in Personalis by 25.6% during the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock worth $198,000 after acquiring an additional 7,000 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Price Performance

Shares of Personalis stock opened at $4.51 on Monday. The firm has a market cap of $399.95 million, a price-to-earnings ratio of -3.52 and a beta of 1.86. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $7.79. The stock has a 50-day simple moving average of $6.09 and a 200-day simple moving average of $4.90.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. As a group, equities research analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on PSNL. HC Wainwright decreased their price objective on Personalis from $9.00 to $8.50 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Guggenheim began coverage on Personalis in a research report on Thursday, May 15th. They set a “buy” rating and a $6.00 price objective for the company. Finally, Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.58.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.